Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Sales: 2011-2025

Historic Return on Sales for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -2.96%.

  • Lineage Cell Therapeutics' Return on Sales fell 66.00% to -2.96% in Q3 2025 from the same period last year, while for Sep 2025 it was -2.96%, marking a year-over-year decrease of 66.00%. This contributed to the annual value of -1.96% for FY2024, which is 45.00% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Return on Sales is -2.96%, which was down 2.24% from -2.90% recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Return on Sales registered a high of -0.76% during Q3 2022, and its lowest value of -8.78% during Q1 2021.
  • Moreover, its 3-year median value for Return on Sales was -2.40% (2023), whereas its average is -2.55%.
  • In the last 5 years, Lineage Cell Therapeutics' Return on Sales spiked by 1,121bps in 2021 and then slumped by 187bps in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Return on Sales (Quarterly) stood at -0.79% in 2021, then tumbled by 100bps to -1.79% in 2022, then plummeted by 61bps to -2.40% in 2023, then soared by 45bps to -1.96% in 2024, then crashed by 66bps to -2.96% in 2025.
  • Its last three reported values are -2.96% in Q3 2025, -2.90% for Q2 2025, and -1.89% during Q1 2025.